Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.
A double-'blind', placebo-controlled trial of topical therapy with 15% paromomycin (aminosidine) and 10% urea in white paraffin was carried out on 53 patients with non-ulcerating cutaneous leishmaniasis in Honduras. Although the treatment was not effective, several unexpected findings emerged from the trial. Leishmania mexicana was found to be the cause of many of the skin lesions in one of the 2 study sites. These lesions were clinically indistinguishable from those caused by L. chagasi, the aetiologic agent previously found for this form of leishmaniasis. This is the first documented report of L. mexicana in Honduras.
Neva
F A
FA
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ponce
C
C
Ponce
E
E
Kreutzer
R
R
Modabber
F
F
Olliaro
P
P
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006721:Honduras; D006801:Humans; D007894:Leishmania mexicana / Q000302:isolation & purification; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D008297:Male; D010303:Paromomycin / Q000008:administration & dosage*; D012867:Skin / Q000473:pathology
D000981:Antiprotozoal Agents; D010303:Paromomycin